"TP-6076 is the lead candidate selected from our second-generation discovery program because it has demonstrated potent activity against difficult-to-treat Gram-negative pathogens in preclinical studies, including carbapenem-resistant Enterobacteriaceae (CRE) and carbapenem-resistant Acinetobacter baumannii (CRAB)," said Patrick Horn, Chief Medical Officer of Tetraphase.
"As new antibiotic treatment options are needed to help address the rising threat of antibiotic resistance, we are pleased to advance TP-6076 as our third antibiotic candidate in ongoing clinical trials."
The phase 1 randomized, placebo-controlled, double-blind, sequential-cohort, single-ascending dose study is evaluating the safety and pharmacokinetics of TP-6076.
The study is being conducted under a Clinical Trial Authorization in a single center in up to 32 healthy volunteers. This is the first study in the phase 1 clinical program for TP-6076 which is also expected to include a multiple-ascending dose study.